Accelerating PROTACS Drug Discovery with One-Stop TPD Solutions
Join industry experts for this webinar that will include two insightful topics of discussion!
Part 1: One-stop degrader in vitro profiling
Targeting proteins for degradation therapeutically, as an alternative to inhibiting them, holds great promise for treating diseases in which pathogenic proteins are considered "undruggable" due to a lack of active sites for conventional small molecules. To discover such compounds, there are several challenges that need to be addressed to successfully facilitate and expedite TPD drug discovery. We’ll explore these challenges in more detail, as well as take a look at TPD platforms and how they can be effective solutions for resolving key issues.
Part 2: Chemistry synthesis service for PROTACs drug discovery
PROTACs (PROteolysis TArgeting Chimeras) have emerged as a new and promising modality in medicinal discovery, and research into their potential is currently a very active area. A PROTAC is a heterobifunctional molecule that consists of a protein-of-interest (POI) ligand and an E3 ubiquitin ligase (E3) recruiting ligand, connected by a linker. Learn more about the synthesizing of PROTAC molecules, the latest tools and strategies for making this work more efficient, and how this can lead to faster drug discovery.